News from vivus, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 16, 2013, 14:30 ET

VIVUS Announces FDA Approval of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies

 VIVUS, Inc. (Nasdaq: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved its amendment and modification to the...

Apr 10, 2013, 07:00 ET

New Obesity Education Program To Premiere At American College of Physicians (ACP) Annual Meeting

A new educational program, Excess Weight and Your Health: A Guide to Effective, Healthy Weight Loss, developed by the Obesity Action Coalition...

Mar 25, 2013, 06:00 ET

Analysis In Health Economics Review Concludes Effective Medical Obesity Treatment Could Reduce Medicare Spending

 VIVUS, Inc. (Nasdaq:  VVUS) announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight...

Mar 07, 2013, 07:00 ET

VIVUS Launches Mobile App to Help Patients Lose Weight

 VIVUS, Inc. (Nasdaq: VVUS) announced today the launch of the Q and Me™ app, a no-cost mobile app available through iTunes and...

Mar 05, 2013, 07:00 ET

VIVUS Announces New Qsymia Offer

 VIVUS, Inc. (Nasdaq:  VVUS) today announced a new program offering eligible patients a discount on Qsymia® (phentermine and...

Feb 01, 2013, 07:00 ET

Study Concludes That Weight Loss With Qsymia™ Significantly Improves Multiple Cardiovascular Disease Risk Factors

VIVUS, Inc. (Nasdaq: VVUS) announced today the publication of a study concluding that weight loss resulting from treatment with QsymiaTM...

Dec 20, 2012, 06:30 ET

VIVUS Announces Express Scripts Adds Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV To Its Standard Benefits Program

 VIVUS, Inc. (NASDAQ: VVUS) today announced that Express Scripts, among the country's largest Pharmacy Benefit Managers (PBMs), has added...

Nov 12, 2012, 07:00 ET

Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules

 VIVUS, Inc. (NASDAQ: VVUS) today announced that a study published in the journal SLEEP (2012; 35(11):1529-1539) found that patients with...

Oct 17, 2012, 07:00 ET

VIVUS Submits REMS Amendment To FDA For Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV

 VIVUS, Inc. (NASDAQ: VVUS) today announced that it has submitted an amendment to the Risk Evaluation and Mitigation Strategy (REMS) for...

Oct 08, 2012, 07:00 ET

Express Scripts Joins Qsymia™ (Phentermine And Topiramate Extended-Release) Certified Home Delivery Pharmacy Network

 VIVUS, Inc. (NASDAQ: VVUS) today announced that Express Scripts, the country's largest Pharmacy Benefit Manager (PBM), has joined the...

Sep 20, 2012, 07:00 ET

VIVUS To Present New Data On Qsymia™ At 30th Annual Scientific Meeting of The Obesity Society

VIVUS, Inc. (Nasdaq:VVUS) today announced that multiple scientific abstracts will be presented at Obesity 2012, the 30th Annual Scientific Meeting...

Sep 18, 2012, 07:00 ET

VIVUS Announces Availability Of Once Daily Qsymia™ (Phentermine And Topiramate Extended-Release) Capsules CIV

 VIVUS, Inc. (NASDAQ: VVUS) today announced the U.S. market availability of Qsymia™ (pronounced Kyoo sim ee' uh). Qsymia is FDA-approved...

Jul 17, 2012, 21:14 ET

Vivus Announces FDA Approval of Once Daily Qsymia™ (Phentermine and Topiramate Extended-release) Capsules CIV

VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved Qsymia™ (pronounced Kyoo sim ee' uh)...

Apr 27, 2012, 15:41 ET

Vivus Announces FDA Approval Of STENDRA™ (avanafil) Tablets For The Treatment Of Erectile Dysfunction

VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the...

Feb 22, 2012, 17:55 ET

FDA Advisory Committee Recommends Approval of Qnexa®

 VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee...

Jan 17, 2012, 06:45 ET

REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function

 VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the REVIVE study were published in The Journal of Sexual Medicine (JSM), a...

Jan 09, 2012, 06:45 ET

VIVUS Provides Qnexa Regulatory Update

 VIVUS, Inc. (NASDAQ: VVUS) today announced that following recent discussions with Food and Drug Administration (FDA) officials, the company...

Jan 04, 2012, 06:45 ET

VIVUS to Present at the 2012 JP Morgan Healthcare Conference

VIVUS, Inc. (NASDAQ: VVUS) today announced that the Company will present at the 30th Annual JP Morgan Healthcare Conference. The VIVUS...

Dec 23, 2011, 06:45 ET

VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity

 VIVUS, Inc. (NASDAQ: VVUS) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and...

Dec 21, 2011, 16:00 ET

VIVUS Reports Topline Findings From FORTRESS

 VIVUS, Inc. (NASDAQ: VVUS) today announced topline preliminary results from its retrospective study of medical claims data on oral clefts...